clinical trial · NCT06866574
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University·phase3·active not recruiting·n = 9,300
Penile/Perineal /Perianal Intraepithelial NeoplasiaAnal Intraepithelial NeoplasiaPenile/Perianal/Perineal CancerAnal CancerGenital WartsRecombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)Aluminum Adjuvant
brief summary
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in Chinese males aged 18-45 years.
started
Apr 11, 2025
primary completion
Sep 30, 2031
completion
Sep 30, 2031
last updated
Jul 31, 2025
official title
A Multicenter, Randomized, Double-Blind, Aluminum Adjuvant-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E. Coli) in Chinese Males Aged 18 to 45 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol